Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × Anastrozole × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 60 Neoplasms 10 Neoplasm Metastasis 8 Advanced Breast Cancer 4 Neoplasms by Site 2 Breast Diseases 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Diseases 1 Recurrence 1 Quality of Life 1 Patient Compliance 1 Ovarian Neoplasms 1 Osteoporosis 1 Multiple Endocrine Neoplasia Type 1 1 Low Grade Serous Ovarian Cancer 1 Lethal Congenital Contracture Syndrome 2 1 Joint Diseases 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Metastatic 1 Bone Diseases, Metabolic 1 Bone Density 1 Arthralgia 1 Advanced Metastatic Breast Cancer 1

Interventions

Dexamethasone 46 Cyclophosphamide 28 Lenalidomide 27 pomalidomide 24 Rituximab 23 venetoclax 22 fludarabine 21 Bortezomib 20 Paclitaxel 18 Gemcitabine 18 carfilzomib 16 Carboplatin 15 pembrolizumab 14 Cisplatin 14 daratumumab 13 Docetaxel 12 Calcium Dobesilate 12 Cytarabine 11 Azacitidine 11 obinutuzumab 10 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 ibrutinib 9 durvalumab 8 blinatumomab 8 Injections 8 Cetuximab 8 zanubrutinib 7 selinexor 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡